2026 Q1
SunRay101 antibody screening expected to be completed in Q1 2026.
Regenerative Biomaterials:
Regenerative Biomaterials:
AI-Powered Innovation in Implantable Medical Devices
AI-Powered Innovation in Implantable Medical Devices
- Traditional biomaterial R&D cycles span 5–8 years; marketed aesthetic regenerative materials suffer from homogeneity, non-uniform particle sizes, and widespread inflammatory responses.
- Fillers provide only transient effects; bone repair materials lack bioactivity, leaving patients without optimal tissue regeneration outcomes.
SUNRAY Approach
Our AI-assisted Biomaterial Composite Design Platform leverages multi-physics simulation and performance prediction to precisely guide material composition and degradation kinetics design, reducing experimental workload by over 50% and shortening Class III medical device registration timelines by more than one year. Core products include PLLA poly-L-lactic acid microspheres (facial rejuvenation), ECM extracellular matrix composite scaffolds (bone repair), and recombinant type III collagen (wound/scar repair).
Indications
Facial volume loss, bone defects, chronic wounds, scar revision, and beyond.
Clinical Value
Delivering next-generation regenerative biomaterials with independent intellectual property for the aesthetic, orthopedic, and trauma care markets, enabling tissue reconstruction from structure to function.
Technology Infrastructure
R&D across all four application domains is supported by the following three technology platforms:
Metabolic Disease Therapeutics
Musculoskeletal Regeneration
Regenerative Biomaterials
Smart Health Management
AI De Novo Antibody Platform
Directly generates antibodies against antigen epitopes, reducing R&D costs by 70%
AI Cell Screening Platform
Tens of millions of data points accumulated; participates in industry standard-setting
AI Biomaterial Composite Design Platform
Multi-physics simulation reduces experimental workload by over 50%
Key Milestones
-
-
2026
China's first tendon stem cell IIT clinical trial was approved at the Second Affiliated Hospital of Zhejiang University.
-
2026 Q2
PLLA microspheres have completed enrollment of 240+ patients (Class III medical device).
-
2026
Longevity Clinic to be established in 2026.
